Consensus Guidelines for Persistent Chemotherapy-Induced Alopecia
New guidelines have been created to standardize the definition, diagnosis, and treatment of persistent chemotherapy-induced alopecia (pCIA). These evidence-based recommendations aim to assist clinicians in managing this complex condition.
Development Process
The guidelines were published in the Journal of the European Academy of Dermatology & Venereology following a Delphi consensus study. An international panel of 15 dermatology experts specializing in supportive oncodermatology and cancer-related hair disorders collaborated to establish unified definitions, diagnostic criteria, grading methods, and treatment recommendations for pCIA.
The Delphi process was conducted anonymously online from January to June 2024. It involved rating survey statements, formed through a comprehensive literature review across four databases, using a 5-point Likert scale. A strong consensus was reached on 75.8% of the statements assessed.
Definitions
- Persistent chemotherapy-induced alopecia (pCIA): nonscarring hair loss lasting longer than six months after completing chemotherapy.
- Endocrine therapy-induced alopecia (EIA): hair loss occurring after full hair regrowth post-chemotherapy, attributed to endocrine therapy and confirmed by a healthcare professional.
Clinical Utility
These unified guidelines offer a practical resource for clinicians, especially those less experienced in addressing the complex needs of cancer survivors dealing with alopecia.
The establishment of standardized criteria and management strategies will help improve patient care and support for individuals suffering long-term hair loss after cancer treatment.
Author’s summary: International consensus guidelines now provide clear definitions and evidence-based recommendations to better diagnose and manage persistent chemotherapy-induced alopecia in cancer survivors.